Announced details
Multiple myeloma
The company will present BP2202 research results and the Phase I clinical trial design at IMS 2026.
The organizer of IMS 2026, an international conference in the field of multiple myeloma. Location, representative, capital and year established: Not disclosed
Glasgow, Scotland, United Kingdom (venue for IMS 2026)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | BP2202 (iPS cell-derived BCMA CAR-NKT cell therapy / iPS cell-derived off-the-shelf BCMA-targeted cell therapy) |
| Counterparty | International Myeloma Society |
| Counterparty overview | The organizer of IMS 2026, an international conference in the field of multiple myeloma. Location, representative, capital and year established: Not disclosed |
| Relationship with the Company | The company will present BP2202 research results and the Phase I clinical trial design at IMS 2026. |
| Launch date | 23–26 September 2026 (scheduled presentations) |
| Applicable area | Multiple myeloma |
| Location | Glasgow, Scotland, United Kingdom (venue for IMS 2026) |
| Location scale | More than 3,000 participants expected |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the research results and clinical trial design for BP2202, for which the company has obtained FDA authorization to conduct a clinical trial and has begun a U.S. Phase I clinical trial.